Spherix Inc. (SPEX) Reports Progress On Phase 3 Trial for Diabetes Drug
Spherix Inc. reported progress on a Phase 3 clinical trial for its new drug to treat Type 2 diabetes and expects results in the third quarter of 2010. Spherix is developing D-tagatose, which is used to reduce blood sugar levels in patients suffering from Type 2 diabetes. D-tagatose works by decreasing glycogen utilization in the body, which leads to better control of blood sugar. Spherix has two clinical trials underway for D-tagatose with the Food and Drug Administration (FDA) under the Investigational New Drug Application (NDA) format with the agency. The company has a Phase 2 trial to evaluate D-tagatose…